RxDoctor Payments Data

Tina Bumgarner

Nurse Practitioner · Carolina Shor, NCNPI 1598932683

Payments from drug & device makers

$955in general payments, 2019–2025

Across 50 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$209
  • AbbVie$205
  • Novo Nordisk$159
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$56
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$49
  • Exact Sciences$37
  • plus $241 from 10 others

What the payments were for

  • Food & beverage$955100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$955 in reported general payments places this provider in the 75th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$39,404
Medicare patients
90
Services billed
531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$75,633
TrulicityDulaglutide37$54,168
JardianceEmpagliflozin43$39,326
FarxigaDapagliflozin Propanediol19$18,938
RybelsusSemaglutide12$16,865
Repatha SureclickEvolocumab25$15,700
MounjaroTirzepatide13$13,638
EliquisApixaban11$13,321
Janumet XrSitagliptin Phos/Metformin Hcl14$10,206
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$6,733
Fenofibrate47$4,770
Novolog FlexpenInsulin Aspart28$4,627
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$4,450
Aripiprazole15$2,144
Gabapentin111$1,385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$159$92,49879 claims
Lilly USA, LLCTrulicity, Mounjaro$16$67,80650 claims
Boehringer IngelheimJardiance$21$39,32643 claims
AstraZenecaFarxiga$209$18,93819 claims
PfizerEliquis$33$13,32111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Carolina Shor

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →